PRF Technologies Highlights Cash Position, OcuRing-K Trial Plans and AI Data Center Opportunity

The company reported preliminary cash, including short-term deposits, of approximately $11.0 million as of September 30, 2026. Its interim CEO outlined plans to enroll patients in a U.S. multicenter Phase 2 trial of OcuRing-K before year-end.